Chronic Lymphocytic Leukemia
Featured Article
Based on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based treatment resulted in sustained efficacy with high…
William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of…
Whether on treatment regimens or watch-and-wait, researchers recently found that patients with chronic lymphocytic leukemia had significantly impaired quality of life compared with age-matched…